Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 83
Filter
1.
BMC Pregnancy Childbirth ; 24(1): 358, 2024 May 14.
Article in English | MEDLINE | ID: mdl-38745136

ABSTRACT

BACKGROUND: Hypertensive disorders of pregnancy (HDP) are the most common cause of postpartum readmission. Prior research led to clinical guidelines for postpartum management; however, the patient experience is often missing from this work. The objective of this study is to understand the perspective of patients readmitted for postpartum hypertension. METHODS: This was a qualitative study with data generated through semi-structured interviews. Patients readmitted with postpartum HDP at an urban academic medical center from February to December 2022 were approached and consented for an interview. The same researcher conducted all interviews and patient recruitment continued until thematic saturation was reached (n = 9). Two coders coded all interviews using Nvivo software with both deductive and inductive coding processes. Discrepancies were discussed and resolved with consensus among the two coders. Themes were identified through an initial a priori template of codes which were expanded upon using grounded theory, and researchers were reflexive in their thematic generation. RESULTS: Six themes were generated: every pregnancy is different, symptoms of preeclampsia are easily dismissed or minimized by both patient and providers, miscommunication regarding medical changes can increase the risk of readmissions, postpartum care coordination and readmission logistics at our hospital could be improved to facilitate caring for a newborn, postpartum care is often considered separately from the rest of pregnancy, and patient well-being improved when conversations acknowledged the struggles of readmission. CONCLUSIONS: This qualitative research study revealed patient-identified gaps in care that may have led to readmission for hypertensive disorders of pregnancy. The specific recommendations that emerge from these themes include addressing barriers to blood pressure management prior to discharge, improving postpartum discharge follow-up, providing newborn care coordination, and improving counseling on the risk of postpartum preeclampsia during discharge. Incorporating these patient perspectives in hospital discharge policy can be helpful in creating patient-centered systems of care and may help reduce rates of readmission.


Subject(s)
Patient Readmission , Postpartum Period , Qualitative Research , Humans , Female , Patient Readmission/statistics & numerical data , Pregnancy , Adult , Postpartum Period/psychology , Hypertension, Pregnancy-Induced/therapy , Puerperal Disorders/therapy , Puerperal Disorders/psychology , Postnatal Care/methods , Interviews as Topic
2.
Pharm Nanotechnol ; 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-38173066

ABSTRACT

BACKGROUND: Lasmiditan (LAS) is a recently developed antimigraine drug and was approved in October, 2019 for the treatment of acute migraines; however, it suffers from low oral bioavailability, which is around 40%. OBJECTIVE: This study aimed to improve the LAS bioavailability via formulation as nanoemulsionbased in situ gel (NEIG) given intranasally and then compare the traditional aqueous-LASsuspension (AQS) with the two successful intranasal prepared formulations (NEIG 2 and NEIG 5) in order to determine its relative bioavailability (F-relative) via using rabbits. METHODS: Two successfully prepared nanoemulsion (NE) formulas, a and b, were selected for the incorporation of different percentages of pH-sensitive in situ gelling polymer (Carbopol 934) to prepare NEIGs 1, 2, 3, 4, 5, and 6. The pH, gelation capacity, gel strength, and viscosity were predicted for the prepared NEIGs. The release (in vitro) and the nasal permeation (ex vivo) were determined for NEIG 2 and 5, and then both were subjected to pharmacokinetics in vivo studies. Eighteen male rabbits weighing 2.0 to 2.5 kg were employed in the parallel design study. The body surface area (BSA) normalization method was applied for LAS dose calculation. Serial blood samples were taken out and subjected to drug analysis using the HPLC method previously developed and validated by L. Santosh Kumar. Primary pharmacokinetics parameters, including maximum drug concentration in plasma (Cmax), time to reach C-max (T-max), and area under the concentration-time curve from time zero to affinity (AUCt0-∞) were calculated. Both NE (a and b), together with NEIG (2 and 5) formulas, were subjected to the stability study. Finally, a nasal ciliotoxicity study was carried out to evaluate the nasal toxicity of developed NEIGs 2 and 5. RESULTS: The results showed that NEIGs 2 and 5 could be selected as the optimized NEIGs as both achieved 100% permeation within 20 min and then released within 25 and 35 min, respectively, thus achieving 3.3 folds with higher permeation percentages as compared to the AQS. Both NEIGs 2 and 5 exerted comparable release and permeation values as the corresponding NE a and b with more residence time in order to overcome the normal nasal physiological clearance. The values of C-max, Tmax, and AUC0- ∞ for NEIG 2 and NEIG 5 were 8066±242 ng/ml, 0.75±0.05 h, 19616.86±589 ng. h/ml, and 7975.67±239 ng/ml, 1.0±0.05 h, 17912.36±537 ng. h/ml, respectively, compared to the traditional AQS, which is equal to 4181.09±125 ng/ml, 2±0.2 h, and 8852.27±266 ng. h/ml, respectively. It was discovered that NEIGs 2 and 5 had better intranasal delivery of LAS and could significantly (p<0.05) achieve a higher value of permeability coefficient (3.3 folds) and 2.5 folds improvement in bioavailability when compared to AQS. The NE a, NE b, NEIG2, and NEIG5 formulations showed good stability at various temperatures. According to the nasal ciliotoxicity study, the nasal mucosal membrane, which was treated with NEIG 5, showed irritation with a bit of damage. However, damage was not observed when it was treated with NEIG 2, indicating the biocompatibility of the last one to be selected as the optimum formula. CONCLUSION: NEIG 2 and NEIG 5 are promising new intranasal formulas with a faster onset of action and greater bioavailability than the oral dosage form (AQS). Finally, the selected optimum gold formula that will be ready for further clinical study is NEIG 2.

3.
Am J Perinatol ; 2023 Mar 07.
Article in English | MEDLINE | ID: mdl-36882097

ABSTRACT

The standard care model in the postpartum period is ripe for disruption and attention. Hypertensive disorders of pregnancy (HDPs) can continue to be a challenge for the postpartum person in the immediate postpartum period and is a harbinger of future health risks. The current care approach is inadequate to address the needs of these women. We propose a model for a multidisciplinary clinic and collaboration between internal medicine specialists and obstetric specialists to shepherd patients through this high-risk time and provide a bridge for lifelong care to mitigate the risks of a HDP. KEY POINTS: · HDPs are increasing in prevalence.. · The postpartum period can be more complex for women with HDPs.. · A multidisciplinary clinic could fill the postpartum care gap for women with HDP..

4.
J Orthod Sci ; 12: 61, 2023.
Article in English | MEDLINE | ID: mdl-38234646

ABSTRACT

OBJECTIVES: The perioral muscles postural and functional abnormality should be clearly evaluated. The influence of the abnormal function of mentalis muscle on the shape and posture of the mandible was evaluated using a finite element approach. METHODS: Finite element analysis was used to create a three-dimensional representation of a human mandible that represents a dry normal mandible with teeth (33-36 gm/cm2). Pressures were applied directly to the labial surface of the mandible's lower anterior dento-alveolar structure reflecting the normal lips muscle function. While on abnormal swallowing pattern, lip muscle force (300 gm\cm2) had been assumed. RESULTS: Shape and postural abnormality of the mandible with malocclusion particularly at the anterior dentoalveolar and basal bone region in sagittal direction as well as inward pressure on the mandibular posterior region. CONCLUSION: Abnormal perioral muscle function throughout growth and development may result in a shape and postural abnormality of the mandible and a companying malocclusion.

5.
Am J Perinatol ; 2022 Nov 10.
Article in English | MEDLINE | ID: mdl-35973790

ABSTRACT

OBJECTIVE: The Illinois Perinatal HIV Prevention Act was passed to ensure universal HIV testing once during pregnancy and was extended in 2018 to add third trimester repeat HIV screening. The objectives of this analysis were to describe uptake of, and patient factors associated with, third trimester repeat HIV testing at a high-volume birthing center. STUDY DESIGN: This is a retrospective cohort study of people who delivered at a single tertiary care hospital in Illinois during 2018. Women who delivered before 27 weeks, had an intrauterine fetal demise, a known diagnosis of HIV, or no HIV test during pregnancy were excluded. Repeat testing was defined as an HIV test at or after 27 weeks' gestation after an earlier negative HIV test during the same pregnancy. The primary outcome was the proportion of people who received repeat testing prior to delivery. Bivariable analyses were performed to identify patient characteristics associated with documentation of repeat HIV testing. RESULTS: Of 12,053 people eligible for inclusion, 3.4% (n = 414) presented without a documented third trimester repeat HIV test. The proportion of people with repeat testing improved from 80 to >99% in the first year. Patient factors were largely not associated with testing performance although multiparous people were more likely to have documented repeat testing. CONCLUSION: Rapid implementation of third trimester repeat HIV testing was achieved without disparity. Patient factors were largely not associated with testing performance which reinforces the goal of a universal screen to test all people equitably and effectively without bias. KEY POINTS: · Little is known about adherence to repeat third trimester HIV testing in pregnancy.. · Universal third trimester HIV screening was implemented with high uptake and without disparity.. · Protocolization of repeat HIV testing in pregnancy may reduce bias compared to risk based-screening..

6.
J Perinatol ; 41(12): 2730-2735, 2021 12.
Article in English | MEDLINE | ID: mdl-34675372

ABSTRACT

OBJECTIVE: To examine the association between the Weighted Adverse Outcome Score (WAOS) and race/ethnicity among a large and diverse population-based cohort of women and neonates in the United States. STUDY DESIGN: This was a retrospective cohort study of women who delivered in the United States between 2011 and 2013. We identified mother-infant pairs with adverse maternal and/or neonatal outcomes. These outcomes were assigned weighted scores to account for relative severity. The association between race/ethnicity and WAOS was examined using chi-square test and multivariable logistic regression. RESULTS: Compared to White women and their neonates, Black women and their neonates were at higher odds of an adverse outcome. CONCLUSION(S): The vast majority of women and neonates had no adverse outcome. However, Black women and their neonates were found to have a higher WAOS. This tool could be used to designate hospitals or regions with higher-than-expected adverse outcomes and target them for intervention.


Subject(s)
Black People , Ethnicity , Cohort Studies , Female , Humans , Infant, Newborn , Logistic Models , Retrospective Studies , United States/epidemiology
7.
J Oral Biol Craniofac Res ; 11(3): 430-434, 2021.
Article in English | MEDLINE | ID: mdl-34094842

ABSTRACT

OBJECTIVES: The effect of buccinator muscle on the mandible need to be more clarified. Finite element method used to estimate the effect of the buccinator during abnormal function on the size and shape of the mandible. METHODS: Three-dimensional model of human mandible using Finite element analysis referring to dry normal mandible with teeth as a template, The mechanical characteristic of the materials were supposed to be homogenous, isotropic, and linear elastic. Auto mesh order used to discredit the model under analysis to numerous elements; every element includes numbers of apexes called nodes; the association of elements and nodes called the finite element mesh. The force of (2 â€‹gm/cm2) had been applied perpendicular to buccal surface of posterior teeth within the mandible representing normal buccinators muscle function on the mandible. While for simulation of abnormal suckling, buccinators muscle force (21 â€‹gm∖cm2) applied to the same area. RESULTS: abnormal size and shape of the mandible with malocclusion especially at the posterior teeth area in transverse direction in addition to backward pressure on the chin and anterior teeth result from abnormal suckling force. CONCLUSION: It could be concluded that abnormal function of buccinators during growth and development could result in size and shape variation of the mandible with concomitant malocclusion.

8.
J Opt Soc Am A Opt Image Sci Vis ; 37(11): C50-C56, 2020 Nov 01.
Article in English | MEDLINE | ID: mdl-33175731

ABSTRACT

Space division multiplexing (SDM) erbium-doped seven-core fiber amplifiers (EDFAs) are increasingly attracting interest due to their performances in improving capacity transmission systems. To increase the gain and improve the characteristics of the SDM seven-core fiber amplifier, this paper proposes the use of the erbium/ytterbium (Er3+/Yb3+) co-doped seven-core fiber amplifier. A theoretical model of the SDM co-doped seven-core fiber amplifier is developed. The presented results show that the proposed model allows us to obtain a peak gain over 60 dB at a wavelength of 1543 nm, a large bandwidth of 64 nm with a gain greater than 20 dB and with a minimum noise which is lower than 6 dB.

9.
Am J Perinatol ; 37(10): 1038-1043, 2020 08.
Article in English | MEDLINE | ID: mdl-32498092

ABSTRACT

With the coronavirus disease 2019 (COVID-19) pandemic in the United States, a majority of states have instituted "shelter-in-place" policies effectively quarantining individuals-including pregnant persons-in their homes. Given the concern for COVID-19 acquisition in health care settings, pregnant persons with high-risk pregnancies-such as persons living with HIV (PLHIV)-are increasingly investigating the option of a home birth. Although we strongly recommend hospital birth for PLHIV, we discuss our experience and recommendations for counseling and preparation of pregnant PLHIV who may be considering home birth or at risk for unintentional home birth due to the pandemic. We also discuss issues associated with implementing a risk mitigation strategy involving high-risk births occurring at home during a pandemic. KEY POINTS: · Coronavirus disease 2019 pandemic has increased interest in home birth.. · Women living with HIV are pursuing home birth.. · Safe planning is paramount for women living with HIV desiring home birth, despite recommending against the practice..


Subject(s)
Coronavirus Infections/epidemiology , HIV Infections/epidemiology , Home Childbirth/methods , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pregnancy Outcome , Pregnancy, High-Risk , Adult , COVID-19 , Comorbidity , Coronavirus Infections/prevention & control , Counseling , Delivery, Obstetric/methods , Female , Home Childbirth/statistics & numerical data , Humans , Infectious Disease Transmission, Vertical/prevention & control , Pandemics/statistics & numerical data , Patient Safety/statistics & numerical data , Pneumonia, Viral/prevention & control , Pregnancy , Risk Assessment , United States
11.
Am J Perinatol ; 36(10): 1066-1071, 2019 08.
Article in English | MEDLINE | ID: mdl-30508869

ABSTRACT

OBJECTIVE: To evaluate the offer, acceptance, uptake, and patient experience with 17-hydroxyprogesterone caproate (17OHP-C) over the course of 10 years. STUDY DESIGN: This is a retrospective cohort study with a qualitative component. We identified all women with spontaneous preterm deliveries with subsequent births in our hospital between 2005 and 2015. We used linear regression to calculate unadjusted odds ratios for 17OHP-C offer, acceptance, and doses received associated with predictors of interest, and multivariable modeling further adjusted for potential confounders. A grounded theory approach was used to glean recurrent themes surrounding the patient experience. RESULTS: A total of 265 women fit the eligibility criteria; 39.6% were offered 17OHP-C and 83.8% accepted 17OHP-C. The mean number of documented 17OHP-C doses was 15.7 ± 5.4. Women were less likely to be offered 17OHP-C if they had public insurance or if their earliest preterm birth was of greater gestational age. Non-Hispanic black women were documented to have received four fewer doses than white women. We also identified recurrent themes that hindered acceptance and adherence to 17OHP-C: insurance difficulties, unstable housing, lack of childcare, and job inflexibility. CONCLUSION: Women at a risk of preterm birth are more likely to be offered and receive 17OHP-C if they have private insurance and have had an earlier preterm birth. Non-Hispanic black women were documented to have received fewer doses of 17OHP-C than white women. Further inquiry into the structural causes that lead to disparities in care for women at a risk for preterm birth is important.


Subject(s)
17 alpha-Hydroxyprogesterone Caproate/therapeutic use , Healthcare Disparities/statistics & numerical data , Premature Birth/prevention & control , Progestins/therapeutic use , Adult , Female , Humans , Insurance Coverage , Insurance, Health , Linear Models , Massachusetts , Pregnancy , Racial Groups , Retrospective Studies
12.
J Biomed Opt ; 20(5): 051020, 2015 May.
Article in English | MEDLINE | ID: mdl-25581495

ABSTRACT

The ability to conduct highly localized delivery of contrast agents, viral vectors, therapeutic or pharmacological agents, and signaling molecules or dyes to live mammalian embryos is greatly desired to enable a variety of studies in the field of developmental biology, such as investigating the molecular regulation of cardiovascular morphogenesis. To meet such a demand, we introduce, for the first time, the concept of employing optical coherence tomography (OCT)-guide microinjections in live mouse embryos, which provides precisely targeted manipulation with spatial resolution at the micrometer scale. The feasibility demonstration is performed with experimental studies on cultured live mouse embryos at E8.5 and E9.5. Additionally, we investigate the OCT-guided microinjection of gold­silica nanoshells to the yolk sac vasculature of live cultured mouse embryos at the stage when the heart just starts to beat, as a potential approach for dynamic assessment of cardiovascular form and function before the onset of blood cell circulation. Also, the capability of OCT to quantitatively monitor and measure injection volume is presented. Our results indicate that OCT-guided microinjection could be a useful tool for mouse embryonic research.


Subject(s)
Embryo, Mammalian/pathology , Tomography, Optical Coherence/instrumentation , Tomography, Optical Coherence/methods , Animals , Dextrans/administration & dosage , Equipment Design , Gold/chemistry , Heart/embryology , Imaging, Three-Dimensional , Metal Nanoparticles/chemistry , Mice , Microinjections , Nanomedicine , Silicon Dioxide/chemistry , Sodium Chloride/administration & dosage , Time Factors , Yolk Sac/pathology
14.
Gynecol Oncol ; 135(1): 54-7, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25088333

ABSTRACT

OBJECTIVE: To evaluate whether the presence of mucinous differentiation influences histopathologic findings, stage distribution, or rate of recurrence among women with grade 1, endometrioid type, endometrial carcinoma. METHODS: This was a retrospective cohort study of all patients with grade 1, endometrioid type, endometrial carcinoma between January 2005 and December 2012. Patients were separated by the presence or absence of mucinous differentiation and then compared. RESULTS: Of 655 patients, mucinous differentiation was present in 137 (20.9%) and absent in 518 (79.1%) patients. Compared to the group without mucinous differentiation, the group containing mucinous differentiation was older at diagnosis (mean: 61.1 vs. 58.5 years, OR, 95% CI; 1.03, 1.01-1.05) and more likely to have myometrial invasion (61.3% vs. 51.5%, OR, 95% CI; 1.49, 1.01-2.19). Additional histopathologic findings including: tumor size, cervical stromal invasion, adnexal involvement, LVI and/or the presence of positive lymph nodes were similar between groups. Mucinous differentiation did not affect stage distribution, as most patients were stage 1A (85.4% vs. 86.3%). The median PFS for the entire group has yet to be reached. The mean PFS for the entire study sample was 94.7 months. There was no difference in mean PFS when comparing the group with mucinous differentiation to the group without mucinous differentiation (98 vs. 93.4 months, p=0.07). CONCLUSIONS: In the setting of grade 1, endometrioid type, endometrial carcinoma, mucinous differentiation is more common in older patients and is associated with an increased likelihood of myometrial invasion. However, stage distribution and risk of recurrence are not affected.


Subject(s)
Carcinoma, Endometrioid/epidemiology , Carcinoma, Endometrioid/pathology , Endometrial Neoplasms/epidemiology , Endometrial Neoplasms/pathology , Neoplasm Recurrence, Local/epidemiology , Adenocarcinoma, Mucinous/pathology , Aged , Cell Differentiation , Cohort Studies , Female , Humans , Middle Aged , Neoplasm Grading , Neoplasm Staging , Retrospective Studies , Risk
15.
J Biomed Opt ; 17(8): 081410-1, 2012 Aug.
Article in English | MEDLINE | ID: mdl-23224171

ABSTRACT

Mouse models of ocular diseases provide a powerful resource for exploration of molecular regulation of eye development and pre-clinical studies. Availability of a live high-resolution imaging method for mouse embryonic eyes would significantly enhance longitudinal analyses and high-throughput morphological screening. We demonstrate that optical coherence tomography (OCT) can be used for live embryonic ocular imaging throughout gestation. At all studied stages, the whole eye is within the imaging distance of the system and there is a good optical contrast between the structures. We also performed OCT eye imaging in the embryonic retinoblastoma mouse model Pax6-SV40 T-antigen, which spontaneously forms lens and retinal lesions, and demonstrate that OCT allows us to clearly differentiate between the mutant and wild type phenotypes. These results demonstrate that OCTin utero imaging is a potentially useful tool to study embryonic ocular diseases in mouse models.


Subject(s)
Disease Models, Animal , Retinal Neoplasms/embryology , Retinal Neoplasms/pathology , Retinoblastoma/embryology , Retinoblastoma/pathology , Retinoscopes , Tomography, Optical Coherence/instrumentation , Animals , Equipment Design , Equipment Failure Analysis , Humans , Mice , Mice, Transgenic , Phenotype , Prenatal Diagnosis/instrumentation , Reproducibility of Results , Sensitivity and Specificity
16.
J Biomed Opt ; 16(4): 046004, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21529073

ABSTRACT

Although the mouse is a superior model to study mammalian embryonic development, high-resolution live dynamic visualization of mouse embryos remain a technical challenge. We present optical coherence tomography as a novel methodology for live imaging of mouse embryos through the uterine wall thereby allowing for time lapse analysis of developmental processes and direct phenotypic analysis of developing embryos. We assessed the capability of the proposed methodology to visualize structures of the living embryo from embryonic stages 12.5 to 18.5 days postcoitus. Repetitive in utero embryonic imaging is demonstrated. Our work opens the door for a wide range of live, in utero embryonic studies to screen for mutations and understand the effects of pharmacological and toxicological agents leading to birth defects.


Subject(s)
Embryonic Development/physiology , Mice/embryology , Tomography, Optical Coherence/methods , Animals , Embryo, Mammalian/anatomy & histology , Female , Pregnancy
17.
Leuk Res ; 32(4): 587-91, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17881052

ABSTRACT

Chronic myelomonocytic leukemia (CMML) characterized by cytopenias, bone marrow and peripheral blood cell dysplasia is notoriously hard to treat. Recent reclassification of CMML as a myelodysplastic/myeloproliferative (MDS/MPS) disease rather than a myelodysplastic syndrome (MDS) by the World Health Organisation (WHO) has led to a review of CMML patients treated with decitabine. Overall response rates (ORR) (complete response [CR]+partial response [PR]) in the subset of patients with CMML in one pivotal phase 3 trial (D-0007) and two phase 2 trials (PCH 95-11, PCH 97-19) decitabine were reviewed. For consistency across trials, all decitabine-treated patients were evaluated using the phase 2 response criteria (CR was defined by normocellular bone marrow with <5% blasts and normal Hgb, WBC, and platelet counts, and PR required 50% decrease in blast count, increases in Hgb by >1.5 mmol/L, WBC count by >1000, and platelet count by >50,000). A total of 31 patients diagnosed with CMML are included in this review. Similar demographics and disease characteristics were observed in all three studies, with an average age of 70.2 years and 71% of patients male. Baseline WBC of >20,000 were observed in 8/28 (29%) patients and baseline bone marrow blasts >5% in 11/28 (39%) patients. All clinical responses were centrally reviewed. The ORR was 25% (14% CR+11% PR). Hematologic improvement was observed in 11% of patients and stable disease in 39% of patients. The decitabine adverse event profile seen in CMML patients was similar to observations in other hematologic patient populations, with myelosuppression and related infectious complications. These data demonstrate encouraging activity for decitabine in CMML, and suggest that studies in other myeloproliferative diseases may be warranted.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Azacitidine/analogs & derivatives , Leukemia, Myelomonocytic, Chronic/drug therapy , Aged , Aged, 80 and over , Azacitidine/therapeutic use , Bone Marrow/pathology , Clinical Trials, Phase II as Topic , Clinical Trials, Phase III as Topic , Cytogenetic Analysis , Decitabine , Female , Humans , Male , Middle Aged , Multicenter Studies as Topic , Prognosis , Randomized Controlled Trials as Topic , Survival Rate , Treatment Outcome
18.
Haemophilia ; 9(1): 131-6, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12558792

ABSTRACT

Management of bleeding in haemophiliacs with a history of inhibitor remains problematic. With infusion of factor VIII (FVIII), development of an anamnestic response and possible appearance of high-titre inhibitor remains a valid concern. We report a case of a haemophiliac with a history of moderately high-titre FVIII inhibitor that had become undetectable. He had not received FVIII since 1997, when he became inhibitor negative. He had been managed during his bleeding episodes with prothrombin complex factor concentrates, which became less effective in controlling his bleeding. The patient had a history of recurrent, spontaneous shoulder joint dislocations with bleeding, pain and significant disability. Shoulder joint replacement surgery was suggested. Replacement therapy was discussed with the patient, who refused treatment with human FVIII because of his concern for possible anamnestic response and inhibitor rebound. Porcine FVIII was not acceptable due to his poor response when used once in the past, and his history of moderate allergic reaction. Therefore, recombinant factor VIIa (NovoSeven, Novo Nordisk, Princeton, NJ) was considered to be an acceptable option for the contemplated shoulder surgery. The patient underwent 2.5 h of surgery with NovoSeven infusion. The surgeons were impressed with the lack of bleeding in this traumatic surgery. Despite the continuously prolonged activated partial thromboplastin time and low FVIII levels, the patient maintained a remarkably dry surgical field. Effective haemostasis was achieved during and after this procedure. This case illustrates the usage of NovoSeven as an effective treatment modality in a haemophilia A patient with past history of inhibitor undergoing joint surgery.


Subject(s)
Arthroplasty, Replacement , Factor VIII/antagonists & inhibitors , Factor VII/therapeutic use , Hemophilia A/drug therapy , Hemostasis, Surgical/methods , Recombinant Proteins/therapeutic use , Adult , Factor VIIa , Humans , Male , Shoulder Dislocation/surgery
19.
Am J Hematol ; 66(1): 23-7, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11426487

ABSTRACT

A Phase II study of GM-CSF with intermediate-dose cytarabine and mitoxantrone was conducted in patients with high-risk myelodysplastic syndrome. It was designed to evaluate if priming with growth factor could increase the efficiency of chemotherapy. In this older population only two of 10 patients achieved a bone marrow CR, including one patient whose leukemic blasts had an "S" phase increase of 2.55x at 48 hr. Unexpected hepatotoxicity was noted. This regimen cannot be recommended for this elderly population of patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Granulocyte-Macrophage Colony-Stimulating Factor/therapeutic use , Myelodysplastic Syndromes/drug therapy , Aged , Anemia, Refractory, with Excess of Blasts/drug therapy , Anemia, Refractory, with Excess of Blasts/mortality , Anemia, Refractory, with Excess of Blasts/pathology , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Marrow/pathology , Chemical and Drug Induced Liver Injury/etiology , Cytarabine/administration & dosage , Cytarabine/adverse effects , DNA Replication/drug effects , Female , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Humans , Hyperbilirubinemia/chemically induced , Leukemia, Myelomonocytic, Chronic/drug therapy , Leukemia, Myelomonocytic, Chronic/mortality , Leukemia, Myelomonocytic, Chronic/pathology , Male , Middle Aged , Mitoxantrone/administration & dosage , Mitoxantrone/adverse effects , Myelodysplastic Syndromes/mortality , Myelodysplastic Syndromes/pathology , Pancytopenia/chemically induced , Pancytopenia/drug therapy , Pilot Projects , Recombinant Proteins , Remission Induction , S Phase/drug effects , Treatment Failure
SELECTION OF CITATIONS
SEARCH DETAIL
...